原文：
A technique developed by Vancouver doctors to replace worn-out artificial heart valves without major surgery is being lauded as "one of the most exciting events in cardiology in the last 50 years."
The praise comes in an editorial in the current issue
of the journal of the American Heart Association, Circulation, which accompanies a report on the new technique.
Instead of cracking open the chest, doctors insert the new valve through a tiny incision between the ribs or thread it up to the heart through a blood vessel in the leg.
The editorial accompanies a study co-authored and led by St. Paul's Hospital's Dr. John Webb that describes 24 cases in Vancouver, Quebec City, Toronto and London, England in which the new technique was used on high-risk patients with failing artificial valves.
The procedure, first done about five years ago, is called transcatheter valve implantation because after the new valve is placed inside the old one, it pushes the old one out
of the way, where it remains indefinitely. The current study is the first to report on so many cases.
The patients in the study ranged in age from 27 to 87 and all required either a new mitral, aortic, pulmonary or tricuspid valve. The youngest patients were born with heart defects and many of them had already had a handful of prior operations going back to infancy or childhood.
Webb said in an interview Tuesday that many of the patients were turned down for open heart surgery because of its riskiness, so the new procedure was offered on compassionate grounds as an as-yet-unproven, but last-ditch therapy.
"All the patients had heart failure and would have continued to deteriorate and die within a year or two. They knew it was a new procedure but they had no
real alternatives," he said.
Dr. Blase Carabello, vice chair of medicine at Baylor College of Medicine, said in his editorial on the technique that "The advent of [the minimally invasive procedure] is one of the most exciting events in cardiology in the last 50 years, and the work by Webb et al published here
exemplifies the speed with which this technology is advancing."
For the past five to 10 years, Webb has been recognized internationally as a leading innovator of such minimally invasive procedures.
He has trained doctors around the world in his techniques and at least one of the patients in the study was an American who came to Vancouver, seeking Webb's expertise.
Of the 24 patients, 18 were treated in Vancouver, four
in Toronto, one in Quebec City and one in London, England.
Two deaths occurred and are attributed to the procedure; one mitral valve replacement patient suffered a stroke and kidney failure, dying the next day after the procedure while another patient died 45 days later.
The 30-day survival rate for all patients was 96 per cent but the longer term survival rate (after recorded follow-ups ranging from 135 to 1,045 days) was 91.7 per cent.
原文来自： http://www.shreveporttimes.com/article/20091205/NEWS01/91205007/1060
“Gas line valve release investigated”是由提供的阀门新闻，中文译文仅供参考，以下提供站内导航搜索：
以下是参考译文：
译文：新阀阀植入导管内的旧放置
由温哥华医生开发了一种技术取代传统大手术陈旧的人工心脏瓣膜被称为“最令人兴奋的心脏病在过去50年的事件之一”的真谛。
在1的赞美来在美国心脏协会，流通，其中伴随着对新技术的报告本期杂志的编辑。
而不是打开胸腔破裂，医生通过插入一个肋骨之间或线程它的小切口心脏通过在腿部血管新的阀门。
社论伴随着研究的共同撰写和圣保禄医院的医生约翰韦伯描述
24温哥华，魁北克市，多伦多，伦敦，英格兰案件中，新技术，对高风险患者使用人工瓣膜导致失败。
该程序，首先做5年多前，被称为是因为在新阀阀植入导管内的旧放置，它推动了旧的方式，它仍然是无限期。目前这项研究是首次对如此多的病例报告。
在研究中，患者年龄从27至87及所有需要使用一个新的二尖瓣，主动脉，肺动脉和三尖瓣。最年轻的患者出生时心脏缺陷，其中许多人已经回到了婴儿期或儿童期前业务一小撮。
韦伯在接受采访时表示，周二，许多病人被拒绝了，因为心内直视手术的
风险性，因此新的程序是作为提供恩恤作为前途未卜，但尽{zh1}的xx。
“所有的病人有心脏衰竭，并会继续恶化，一年内死亡或2。他们知道这是一个新的程序，但他们没有真正的替代品，”他说。
布莱思Carabello博士，副医药椅子在贝勒医学院，在他的社论说，在技术，他说：“[微创程序]
的出现，是最激动人心的心脏病在过去50年的活动之一，由韦伯等人发表在这里工作体现了速度，这项技术在进步。“
在过去的5至10年，韦伯已经认识到国际上认为是这种微创手术的{lx1}创新者。
他周围的世界在他的技术和训练有素的医生，至少在研究的患者之一是美国谁来到温哥华，寻求韦伯的专门知识。
在这24例患者，有18人在温哥华，多伦多四个对待，一个在魁北克市，一个在伦敦，英国。
两人死亡发生是由于该程序; 1二尖瓣置换病人中风
和肾功能衰竭，手术后第二天死亡，而另一位病人死亡后45天。
对于所有患者30天存活率为百分之96，但长期存活率（后记录后续行动范围从135至一?四五天）为百分之91.7。
更多新闻
